Feature DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient... September 10, 2019